Posted by Michael Wonder on 12 Jul 2018
ICER releases draft evidence report on anti-androgen therapies for non-metastatic castration-resistant prostate cancer
12 July 2018 - Public comment period now open until 9 August; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness of three anti-androgen therapies for high-risk, nonmetastatic castration-resistant prostate cancer.
he report, which reviews abiraterone acetate (Zytiga, Janssen and Yonsa, Sun Pharma), apalutamide (Erleada, Janssen), and enzalutamide (Xtandi, Astellas and Pfizer), also assesses the value of enzalutamide and apalutamide.
